Neurogene (NGNE) Competitors $19.25 -0.20 (-1.03%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$20.03 +0.78 (+4.04%) As of 07:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NGNE vs. STOK, ZYME, UPB, SION, ORIC, PHAR, SYRE, SPRY, PRAX, and QUREShould you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include Stoke Therapeutics (STOK), Zymeworks (ZYME), Upstream Bio (UPB), Sionna Therapeutics (SION), Oric Pharmaceuticals (ORIC), Pharming Group (PHAR), Spyre Therapeutics (SYRE), ARS Pharmaceuticals (SPRY), Praxis Precision Medicines (PRAX), and uniQure (QURE). These companies are all part of the "pharmaceutical products" industry. Neurogene vs. Its Competitors Stoke Therapeutics Zymeworks Upstream Bio Sionna Therapeutics Oric Pharmaceuticals Pharming Group Spyre Therapeutics ARS Pharmaceuticals Praxis Precision Medicines uniQure Neurogene (NASDAQ:NGNE) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Do insiders and institutionals have more ownership in NGNE or STOK? 52.4% of Neurogene shares are held by institutional investors. 9.9% of Neurogene shares are held by company insiders. Comparatively, 9.5% of Stoke Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, NGNE or STOK? Neurogene has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Does the media favor NGNE or STOK? In the previous week, Stoke Therapeutics had 20 more articles in the media than Neurogene. MarketBeat recorded 24 mentions for Stoke Therapeutics and 4 mentions for Neurogene. Neurogene's average media sentiment score of 1.29 beat Stoke Therapeutics' score of 0.65 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 16 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NGNE or STOK more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Neurogene's net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Neurogene's return on equity.Company Net Margins Return on Equity Return on Assets NeurogeneN/A -33.33% -30.34% Stoke Therapeutics 26.25%18.32%15.48% Which has stronger earnings & valuation, NGNE or STOK? Neurogene has higher earnings, but lower revenue than Stoke Therapeutics. Neurogene is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurogene$930K295.37-$75.14M-$4.31-4.47Stoke Therapeutics$199.89M6.05-$88.98M$0.8525.96 Do analysts rate NGNE or STOK? Neurogene presently has a consensus target price of $46.17, suggesting a potential upside of 139.83%. Stoke Therapeutics has a consensus target price of $25.57, suggesting a potential upside of 15.87%. Given Neurogene's higher possible upside, equities research analysts clearly believe Neurogene is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neurogene 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 SummaryStoke Therapeutics beats Neurogene on 10 of the 17 factors compared between the two stocks. Get Neurogene News Delivered to You Automatically Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NGNE vs. The Competition Export to ExcelMetricNeurogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$277.59M$3.17B$5.83B$10.00BDividend YieldN/A2.28%5.28%4.52%P/E Ratio-4.4721.3475.8226.28Price / Sales295.37426.81514.23172.67Price / CashN/A45.5837.2059.76Price / Book0.9210.0511.666.41Net Income-$75.14M-$53.33M$3.28B$270.56M7 Day Performance-3.12%1.39%1.48%3.13%1 Month Performance-9.28%11.91%11.37%9.74%1 Year Performance-49.25%13.21%61.32%28.17% Neurogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NGNENeurogene2.1813 of 5 stars$19.25-1.0%$46.17+139.8%-45.2%$277.59M$930K-4.4790Positive NewsSTOKStoke Therapeutics4.0484 of 5 stars$21.99+6.3%$25.57+16.3%+43.8%$1.13B$36.56M25.87100Positive NewsZYMEZymeworks0.1499 of 5 stars$15.19+0.9%N/AN/A$1.13B$76.30M-15.66460UPBUpstream Bio2.2375 of 5 stars$18.73-6.2%$56.50+201.7%N/A$1.08B$2.37M0.0038News CoveragePositive NewsSIONSionna TherapeuticsN/A$21.62-9.9%$38.00+75.8%N/A$1.06BN/A0.0035News CoverageAnalyst ForecastHigh Trading VolumeORICOric Pharmaceuticals4.5856 of 5 stars$10.50-3.5%$17.29+64.6%+11.4%$1.06BN/A-5.5680Positive NewsPHARPharming Group2.6626 of 5 stars$14.80-3.0%$30.00+102.7%+112.7%$1.05B$297.20M-113.85280SYRESpyre Therapeutics2.0912 of 5 stars$16.63-2.2%$53.40+221.1%-42.4%$1.03B$890K-4.8973Analyst UpgradeSPRYARS Pharmaceuticals2.8482 of 5 stars$10.70+6.3%$32.50+203.7%-11.9%$995.18M$89.15M-21.8490Analyst RevisionPRAXPraxis Precision Medicines2.653 of 5 stars$40.75-13.0%$85.88+110.7%-32.1%$985.99M$8.55M-3.32110Positive NewsHigh Trading VolumeQUREuniQure2.4608 of 5 stars$17.43-2.9%$37.45+114.9%+225.7%$984.86M$27.12M-4.45500News CoverageAnalyst Forecast Related Companies and Tools Related Companies STOK Alternatives ZYME Alternatives UPB Alternatives SION Alternatives ORIC Alternatives PHAR Alternatives SYRE Alternatives SPRY Alternatives PRAX Alternatives QURE Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NGNE) was last updated on 9/10/2025 by MarketBeat.com Staff From Our Partners“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredWall Street legend: “Put $1,000 in this AI stock”A massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
